FDA approves Hetlioz: first treatment for non-24 hour sleep-wake disorder in blind individuals

The U.S. Food and Drug Administration has approved Hetlioz (tasimelteon), a melatonin receptor agonist, to treat non-24- hour sleep-wake disorder ("non-24") in totally blind individuals. Non-24 is a chronic circadian rhythm (body clock) disorder in the blind that causes problems with the timing of sleep. This is the first FDA approval of a treatment for the disorder.

Full Story →